SLC5A2 and chronic kidney disease: Multivariate Analysis: Additional variables, such as age, comorbidities, duration of chronic kidney disease (CKD) diagnosis, use of Sodium-glucose co-transporter-2 (SGLT2) inhibitors/Angiotensin-converting-enzymes (ACEI)/Angiotensin receptor blocker (ARB), and urine albumin excretion rates will be introduced to better understand the nuances affecting the treatment outcomes.